Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$23.14 - $54.23
Next Earnings Date
May 14 2025
Next Earnings Date
May 14 2025
Latest price
Market Cap | $1.94B |
EV | $1.98B |
Shares Outstanding | 56.39M |
Beta | 1.01 |
Analyst Rating | BUY |
Analyst Target Price | $64.80 |
P/E 2025E | - |
P/Revenue 2025E | 4.54x |
Revenue | 160.10% |
EPS | 12.60% |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | 22.50% |
EPS | - |
Operating Cash Flow | 154.20% |
Free Cash Flow | 128.00% |
Gross Margin 2025E | 77.90% |
Net Profit Margin 2025E | -13.83% |
ROE 2025E | -18.83% |
ROCE 2024 | -37.08% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Mirum Pharmaceuticals, Inc.
MIRM
Sector
Healthcare
Industry
Biotechnology
CEO
Peetz, Christopher
Employees
322
Website
www.mirumpharma.comIPO Date
2019-07-18
Headquarters
950 Tower Lane, Suite 1050, Foster City, California, 94404, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved